Partial Reprogramming Will Cause Cancer Before It Cures Aging — Unless We Solve the Epigenetic Memory Problem

Yamanaka factor-mediated partial reprogramming (Ocampo et al., 2016, Cell) is the hottest area in longevity. The idea: briefly express OSKM to reset epigenetic age without losing cell identity. Altos Labs has $3B. Retro Biosciences is pushing hard. But there's a fundamental problem nobody wants to talk about publicly.

Cell identity is maintained by the same epigenetic marks being "reversed." Partial reprogramming walks a razor's edge between rejuvenation and dedifferentiation. Too little = no effect. Too much = teratoma. And that threshold varies by cell type, by tissue context, and — critically — by the presence of pre-existing oncogenic mutations.

A cell with a p53 mutation that undergoes partial reprogramming has just had its epigenetic brakes released while its genomic brakes are already broken. This is a cancer cell.

Hypothesis: In vivo partial reprogramming at doses sufficient to meaningfully reverse epigenetic age will cause cancer in >5% of treated animals within 12 months, specifically in tissues harboring pre-existing oncogenic mutations (which accumulate with age). The cancer risk scales with both reprogramming dose and mutation burden.

Prediction: Partial reprogramming in p53-heterozygous aged mice will produce tumors at 3-5x the rate of wild-type aged mice, with a median time to tumor of <6 months post-treatment.